Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian CancerAdam D. Steg, Charles N. Landen|Clinical Cancer Research|2011Cited by 368
Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancerZachary C. Dobbin, Charles N. Landen|Oncotarget|2014Cited by 119